ClinicalTrials.gg
RecruitingNCT06043674Updated Oct 21, 2026

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

A Phase 2 interventional study of Glofitamab and Obinutuzumab in Chronic Lymphocytic Leukemia and Richter's Transformation, sponsored by Christine Ryan. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Christine Ryan · Phase 2, Interventional, and Treatment

How we know · 13 judgments

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 21, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 136 open to participants now, 251 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
342nd of 1,298
70 · median 36
Started
2024
with 19 others
Phase 2
546 of 1,501
47 open now
Primary completion
2028-01
later than 158 of 247 live
Registered
1,411th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 342nd largest by planned enrollment of the 1,298 interventional ones that give a count, is one of 20 that started in 2024, is one of 546 in phase 2, reaches primary completion later than 158 of the 247 other live ones, and was the 1,411th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

136 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

131 more — sign in →

All 136 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT).

The names of the study drugs involved in this research study are:

  • Glofitamab (a T-cell bispecific humanized monoclonal antibody)
  • Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody)
  • Polatuzumab vedotin (an antibody-drug conjugate)
  • Pirtobrutinib (a selective inhibitor of BTK)
  • Atezolizumab (a humanized immunoglobulin monoclonal antibody)
  • Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)
Read the detailed description

This is an open-label, multicenter phase II study to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin, pirtobrutinib, or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL).

The U.S. Food and Drug Administration (FDA) has not approved glofitamab, obinutuzumab, polatuzumab vedotin, pirtobrutinib or atezolizumab for RT, but each drug has been approved for other uses.

Glofitamab has been approved by the FDA for certain people with diffuse large B-cell lymphoma (DLBCL), which is similar to Richter's Transformation. Glofitamab has been studied as a single therapy and in combination with polatuzumab vedotin and atezolizumab in people with DLBCL.

Polatuzumab vedotin is already an approved therapy for diffuse large B-cell lymphoma in combination with chemoimmunotherapy.

Pirtobrutinib is an approved therapy for chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

Atezolizumab is an approved therapy for other cancers.

Obinutuzumab is an approved therapy for chronic lymphocytic leukemia.

Tocilizumab is approved for the treatment of an entity called cytokine release syndrome following another therapy called chimeric antigen receptor T-cell therapy; it will be used to treat cytokine release syndrome if a participant develops it in this study.

Study procedures include screening for eligibility, clinic visits for study treatment, blood and urine tests, Positron Emission Tomography (PET) or Computed Topography (CT) scans, bone marrow biopsies, echocardiograms, and electrocardiograms (ECGs).

Participants will receive study treatment for about 9 months and will be followed every 3-6 months for up to 10 years thereafter.

It is expected that about 70 people will take part in this research study.

Genentech, Inc./Loxo Oncology, Inc./Eli Lilly and Company are funding this research study by providing study drugs.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Richter's Transformation

Keywords

  • Chronic Lymphocytic Leukemia
  • CLL
  • Richter's Transformation
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with proven transformation to large B-cell lymphoma (LBCL), consistent with Richter's Transformation. The diagnostic sample must be reviewed by the treating institution.

  • Tumor sample may be obtained by core needle or excisional surgical biopsy.
  • A fresh biopsy is encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided.
  • Biopsy can be obtained up to 3 months prior to first day of treatment.

, defined as ≥1 measurable nodal lesion (long axis >1.5 cm or short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on PET, CT, or magnetic resonance imaging (MRI). Disease should be FDG-avid based on PET.

Cohort-specific eligibility criteria:

  • Glofitamab monotherapy cohort: Patients with either or previously untreated Richter's Transformation.
  • Glofitamab + polatuzumab vedotin cohort: Patients with previously untreated RT. After the first 10 patients are enrolled in this cohort irrespective of prior BTKi exposure status, the remainder of the patients enrolled to this cohort must have previously untreated RT and no prior BTK inhibitor. Patients cannot have prior polatuzumab vedotin exposure.
  • Glofitamab + pirtobrutinib cohort: Patients with previously untreated RT and prior BTK inhibitor exposure (with enrollment to begin only after the first 10 patients are accrued to the polatuzumab combination cohort). Patients cannot have prior pirtobrutinib exposure.
  • Glofitamab + atezolizumab cohort: Patients with relapsed/refractory RT. Patients are required to have received ≥ 1 . Patients cannot have prior atezolizumab exposure.

Age ≥18 years.

performance status of 0-2 (Appendix A).

For patients receiving glofitamab monotherapy, glofitamab in combination with polatuzumab vedotin, or glofitamab in combination with atezolizumab, participants must meet the following organ and marrow function as defined below:

  • must be > 1.0 x109/L (growth factor allowed to achieve), unless patients have significant bone marrow involvement of their confirmed on biopsy.
  • must be > 30 x109/L, independent of transfusion within 7 days of screening, unless patients have bone marrow involvement of their malignancy confirmed on biopsy
  • Creatinine \< 2.0 x (upper limit of normal) or estimated > 50 ml/min according to Cockcroft/Gault formula
  • Total \< 1.5 X ULN

    o Subjects with Gilbert's Syndrome or resolving hemolytic anemia may have a bilirubin up to 3.0 X ULN

  • /ALT \< 3.0 X ULN, unless documented liver involvement by lymphoma

For patients receiving glofitamab in combination with pirtobrutinib, participants must meet the following:

  • Absolute neutrophil count must be > 1.0 x109/L (growth factor >7 days prior allowed to achieve), unless patients have significant bone marrow involvement of their malignancy confirmed on biopsy.
  • > 8 g/dL, independent of transfusion within 7 days of screening, unless patients have bone marrow involvement of their malignancy confirmed on biopsy
  • Platelets must be > 50 x109/L, independent of transfusion within 7 days of screening
  • Estimated CrCl > 50 ml/min according to Cockcroft/Gault formula
  • AST/ALT \< 3.0 X ULN, or \< 5.0 X ULN with documented liver involvement by lymphoma
  • Total bilirubin \< 1.5 X ULN or \< 3.0 x ULN with documented liver involvement by lymphoma and/or Gilbert's Disease
  • Adequate coagulation, defined as (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.
  • The patient is able to take oral medications

Patients who have undergone prior transplantation are potentially eligible if their transplant day 0 is > 6 months from their first dose of treatment and as follows:

For patients receiving glofitamab monotherapy or glofitamab in combination with polatuzumab vedotin, all of the following must additionally be true:

  • No current or prior Grade 3/4 (GVHD)
  • Stable off of for at least 2 months prior to receiving their first dose of treatment on study

For patients receiving glofitamab in combination with pirtobrutinib, all of the following must additionally be true:

  • No active/current GVHD
  • No prior history of Grade 3/4 GVHD
  • Stable off of immunosuppression for at least 2 months prior to receiving their first dose of treatment on study

For patients receiving atezolizumab, no prior allogeneic hematopoietic cell transplantation is allowed.

Willingness to remain abstinent (refrain from heterosexual intercourse) or to use highly effective methods that result in a failure rate of \<1% per year during the treatment period and for at least the following durations listed below:

  • Female patients: at least 18 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 5 months after the last dose of atezolizumab, or 9 months after the last dose of polatuzumab vedotin, or 3 months after the last dose of tocilizumab (if applicable), or 1 month after the last dose of pirtobrutinib, whichever is longest.
  • Male patients: at least 6 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 6 months after the last dose of polatuzumab vedotin, or 2 months after the last dose of tocilizumab (if applicable), whichever is longest.
  • Examples of highly effective contraceptive methods with a failure rate of \<1% per year include: Tubal ligation, male sterilization, hormonal implants, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \<1% per year. Barrier methods must always be supplemented with the use of a spermicide.

For female patients, willingness to refrain from donating ova during the same periods described in section 3.1.6 for female patients. For male patients, willingness to refrain from donating sperm during the same periods described in section 3.1.6 for male patients.

Ability to understand and the willingness to sign a written document. (Providing consents in as many languages as possible is encouraged)

Exclusion criteria

Exclusion Criteria:

Patients with the Hodgkin variant transformation of CLL will be excluded.

No prior anti-CD20 bispecific antibody is allowed. No prior polatuzumab vedotin is allowed for patients in the polatuzumab vedotin-containing combination arm. No prior atezolizumab therapy is allowed for patients in the atezolizumab-containing combination arm. No prior pirtobrutinib is allowed for patients in the pirtobrutinib-containing arm.

Subject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of treatment: agents, targeted therapies, e.g. tyrosine kinase inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not limited to, CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies, radio-immunoconjugates, antibody-drug conjugates1, immune/cytokines and monoclonal antibodies. Patients who are currently receiving treatment with an agent targeting Bruton's tyrosine kinase may continue this agent until the day prior to starting treatment, to reduce the risk of tumor flare on treatment cessation (patients in the pirtobrutinib combination arm may not have received an antibody-drug conjugate within 28 days prior to the first dose of study treatment).

Prior treatment with CAR T-cell therapy within 30 days before first study treatment administration.

Subject has not recovered to less than Grade 1 adverse effect(s)/toxicity from prior anti-cancer therapy including immunotherapy, with the exception of alopecia, endocrinopathy managed with replacement therapy, and stable vitiligo.

Patients with bulky cervical adenopathy that is compressing the upper airway and could result in significant further airway compression during a tumor flare event.

History of other , except:

  • CLL/SLL
  • Malignancy treated with curative intent and with no known active disease present before the first dose of study drug and felt to be at low risk for recurrence by treating physician
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease
  • Low-risk prostate cancer on active surveillance

For patients receiving polatuzumab vedotin: Current > Grade 2 peripheral neuropathy.

Any history of immune-related ≥ Grade 3 AE with the exception of endocrinopathy managed with replacement therapy.

Patient with history of confirmed progressive multifocal leukoencephalopathy (PML).

Current or past history of central nervous system (CNS) disease involvement or history of .

Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease (Note: patients with a history of stroke who have not experienced a stroke or in the past 6 months and have no residual neurologic deficits, as judged by the investigator, are permitted).

History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).

Prior solid organ transplantation.

History of known or suspected hemophagocytic lymphohistiocytosis (HLH).

Active or history of disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

  • Patients with a remote history of, or well controlled, autoimmune disease may be eligible to enroll after consultation with the study PI.
  • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone and patients with controlled Type 1 diabetes mellitus who are on an insulin regimen can be included.
  • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided that the disease is well controlled (Rash \<10% of BSA, and no acute exacerbations requiring methotrexate, retinoids, biologics, or high potency oral ) at baseline and requires only low-potency topical corticosteroids.
  • For patients enrolling to the pirtobrutinib combination arm, patients with the following will be excluded: active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.

Patients who require systemic therapy for an ongoing medical condition will be excluded with the exception of corticosteroid use for disease-related symptom control. Treatment for autoimmune disease with systemic immunosuppressive medications including, but not limited to, prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents are not allowed within 2 weeks prior to Day 1 of Cycle 1.

  • Note the following are permitted: use of inhaled corticosteroids, use of mineralocorticoids for management of orthostatic hypotension.
  • Corticosteroids for lymphoma symptom control is allowed provided patients are on a stable dose as per discretion of the treating investigator and in discussion with the Sponsor-Investigator.

History of severe allergic or anaphylactic reactions to monoclonal antibody therapy unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization.

Patients who have had a major surgery or significant traumatic injury within 2 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).

History of (HIV):

  • For patients receiving glofitamab in combination with pirtobrutinib, patients who have tested positive for HIV are excluded due to risk of opportunistic infections with both HIV and BTK inhibitors. For patients with unknown HIV status, HIV testing will be performed at screening and result must be negative for enrollment.
  • For patients in all other cohorts, only those without controlled disease (controlled disease defined as ≥ 200/uL, undetectable viral load, and stable anti-retroviral therapy) will be excluded.

History of Human T-Cell Leukemia Virus 1 (HTLV-1) infection.

Known active cytomegalovirus (CMV) infection.

Clinically significant liver disease, including cirrhosis and active viral or non-viral hepatitis. Patients who are positive for core antibody or hepatitis B surface antigen must have a negative viral load (by PCR testing), be willing to undergo regular testing, and be able to be treated with a prophylactic agent (e.g. entecavir) if indicated (see Section 5.5). Patients with seropositivity are eligible only if they have a negative viral load (by PCR testing).

Patients with a known active infection.

Patients with any major episode of infection requiring hospitalization within 2 weeks prior to first study drug or treatment-directed antimicrobials within 1 week prior to first study drug. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or exacerbation), antivirals, or antifungals may participate.

Patients should not have received immunization with within 28 days prior to start of study treatment. In addition, patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges. Inactivated influenza vaccination is permitted during influenza season.

Patients with any one of the following currently or in the previous 6 months will be excluded: myocardial infarction, congenital long syndrome, torsade de pointes, unstable angina, or coronary/peripheral artery bypass graft.

Patients with Class III or IV heart failure or with Objective Assessment Class C or D cardiac disease.

For patients receiving pirtobrutinib:

  • Significant cardiovascular disease defined as:

    • unstable angina or acute coronary syndrome within the past 2 months prior to randomization
    • history of myocardial infarction within 3 months prior to randomization or
    • documented by any method of ≤ 40% in the 12 months prior to randomization
  • Uncontrolled or symptomatic arrhythmias

    • Note: patients with atrial fibrillation are allowed as long as they are adequately rate-controlled.)
    • Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
  • Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33).

    • Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.
    • Correction for underlying bundle branch block (BBB) allowed.
  • Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.
  • Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.
  • Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.
  • Have a known to any of the of Pirtobrutinib or to any intended study medications.
  • Patients who experienced a major bleeding event or grade ≥ 3 arrhythmia on prior treatment with a BTK inhibitor. Note: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)
  • History of bleeding disorders (e.g. von Willebrand's disease, hemophilia).
  • History of stroke or intracranial hemorrhage within 6 months of starting study therapy.

Inability to comply with protocol mandated hospitalizations and restrictions.

Patients who are pregnant, breast-feeding, or intending to become pregnant during the study.

Any other diseases, metabolic dysfunction, physical examination finding, mental status or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug.

Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Monotherapy Cohort: Obinutuzumab and Glofitamab

    Study procedures will be conducted as follows: * Baseline visit with screening procedures, including bone marrow biopsy and Positron Emission Tomography (PET) or Computed Topography (CT) scans. * PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment. * Cycle 1: * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily. * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation. * Cycle 2 - 12 --Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for second dose and post-dose observation * End of treatment visit. * Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months. * After completion of a 10-patient safety lead-in cohort, enrollment will open to the other two cohorts.

    Drug: Glofitamab · Drug: Obinutuzumab · Drug: Tocilizumab

  • Experimental
    Combination A Group: Obinutuzumab, Glofitamab, and Polatuzumab Vedotin

    Study procedures will be conducted as follows: * Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans. * PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment. * Cycle 1: * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily. * Day 2 of 21- day Cycle: Predetermined dose of Polatuzumab Vedotin 1x daily. * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation. * Cycle 2 - 6: \- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Polatuzumab Vedotin 1x daily * Cycle 7 - 12 \- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. * End of treatment visit. * Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months.

    Drug: Glofitamab · Drug: Obinutuzumab · Drug: Polatuzumab Vedotin · Drug: Tocilizumab

  • Experimental
    Combination B Group: Obinutuzumab, Glofitamab, and Pirtobrutinib

    Study procedures will be conducted as follows: * Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans. * PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment. * Cycle 1: * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily. * Days 1-21 of 21- day Cycle: Predetermined dose of Pirtobrutinib 1x daily. * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation. * Cycle 2 - 12 \- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Pirtobrutinib 1x daily. Days 2-21 of each cycle: Pirtobrutinib will be taken once daily. * End of treatment visit. * Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months.

    Drug: Glofitamab · Drug: Obinutuzumab · Drug: Tocilizumab · Drug: Pirtobrutinib

  • Experimental
    Combination C Group: Obinutuzumab, Glofitamab, and Atezolizumab

    Study procedures will be conducted as follows: * Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans. * PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment. * Cycle 1: * Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily. * Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation. * Cycle 2 - 12 \- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Atezolizumab 1x daily. * End of treatment visit. * Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months.

    Drug: Glofitamab · Drug: Obinutuzumab · Drug: Atezolizumab · Drug: Tocilizumab

Interventions

  • "2:1" T-cell bispecific humanized monoclonal antibody, administered via intravenous infusion per protocol.

    Also known as: RO7082859

  • Humanized glycoengineered type II anti-CD20 monoclonal antibody, administered via intravenous infusion per protocol.

    Also known as: RO5072759, GA101, GAZYVA, GAZYVARO

  • Antibody-drug conjugate, administered via intravenous infusion per protocol.

    Also known as: Polivy

  • Humanized immunoglobulin monoclonal antibody, administered via intravenous infusion per protocol.

    Also known as: Tecentriq

  • For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, administered via intravenous infusion per protocol.

    Also known as: Actemra

  • Selective inhibitor of BTK, 50 mg or 100 mg tablet, via oral administration per protocol.

    Also known as: Jaypirca

06

What researchers measure

Primary outcomes

  1. Best Complete Response (CR) Rate

    Best Complete Response (CR) rate is defined as the proportion of participants achieving CR at any of the 3 timepoints (after 4, 8 and 12 cycles). CR is defined per Lugano 2014 criteria.

    Time frame: Disease evaluation will be performed at 12, 24 and 36 weeks

Secondary outcomes

  1. Best Overall Response Rate (ORR)

    Best Overall response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) at any of the 3 timepoints (after 4, 8 and 12 cycles). CR and PR are defined per Lugano 2014 criteria.

    Time frame: Disease evaluation will be performed at 12, 24 and 36 weeks

  2. Best Partial Response (PR) Rate

    Best Partial response (PR) rate is defined as the proportion of participants achieving partial response at any of the 3 timepoints (after 4, 8, 12 cycles). PR is defined per Lugano 2014 criteria.

    Time frame: Disease evaluation will be performed at 12, 24 and 36 weeks

  3. Overall Response Rate at 36 weeks

    Overall response rate (ORR) at 36 weeks is defined as the proportion of participants who achieve complete response (CR) or partial response (PR) at the time of disease evaluation at 12 cycles (36 weeks). CR and PR are defined per Lugano 2014 criteria.

    Time frame: 36 weeks

  4. Partial Response (PR) Rate at 36 weeks

    Partial Response (PR) rate at 36 weeks is defined as the proportion of participants achieving PR at the time of disease evaluation at 12 cycles (36 weeks). PR defined per Lugano 2014 criteria.

    Time frame: 36 weeks

  5. Complete Response (CR) Rate at 36 weeks

    Complete Response (CR) rate at 36 weeks is defined as the proportion of participants achieving CR at the time of disease evaluation at 12 cycles (36 weeks). CR defined per Lugano 2014 criteria.

    Time frame: 36 weeks

  6. Duration of Response (DOR)

    Duration of Response (DOR) is defined as the time from date of first documented confirmed objective response (CR + PR) to date of first documented progressive disease (PD) per Lugano 2014 criteria.

    Time frame: Disease evaluation will be performed every 3 months, up to 2 years.

  7. Duration of Complete Response (DOCR)

    Duration of complete response (DOCR) is defined as the time from date of first documented complete response to date of first documented progressive disease (PD) per Lugano 2014 criteria.

    Time frame: In long-term follow-up, participants were assessed every 6 months, up to 2 years

  8. Progression Free Survival (PFS) at 2 years

    PFS at 2 years is the percent probability estimate at 2 years based on the Kaplan-Meier method. PFS will be calculated as the time from start of treatment to the date of progressive disease (PD, defined per Lugano 2014 criteria), death, or last follow-up. Participants alive and progression-free at time of last follow-up will be censored.

    Time frame: Participants will be followed up to 2 years.

  9. Median Progression Free Survival (PFS)

    PFS will be calculated as the time from start of treatment to the date of progressive disease (PD, defined per Lugano 2014 criteria), death, or last follow-up. Participants alive and progression-free at time of last follow-up will be censored.

    Time frame: Participants will be followed up to 2 years.

  10. Overall Survival (OS) at 2 years

    OS at 2 years is the percent probability at 2 years based on Kaplan-Meier methodology. OS will be calculated as the time from the start of treatment to the date of death, or last follow-up. Participants alive at time of last follow-up will be censored.

    Time frame: Participants will be followed up to 2 years.

  11. Median Overall Survival

    OS will be calculated as the time from the start of treatment to the date of death, or last follow-up. Participants alive at time of last follow-up will be censored.

    Time frame: Participants will be followed up to 10 years.

  12. Minimal Residual Disease (MRD) Negativity

    MRD negativity is defined as the proportion of participants that achieve MRD negative, where it measured by multiparametric flow cytometry (Mayo Clinic Laboratories) or the clonoSEQ assay (Adaptive).

    Time frame: MRD testing will be performed every 3 months, up to 2 years, then every 6 months, up to 3 years (5 years in total)

  13. Rate and severity of Cytokine Release Syndrome (CRS), immune effector cell-associated Neurotoxicity Syndrome (ICANS), and Hemophagocytic Lymphohistiocyotis (HLH)

    CRS, ICANS, and HLH rates and severity will be summarized based on American Society of Transplantation and Cellular Therapy (ASTCT) Consensus grading.

    Time frame: Adverse events will be collected at each study visit plus 30 days post treatment end, up to 10 months.

  14. Tocilizumab Usage Rate

    Tocilizumab usage rate is defined as the proportion of participants requiring tocilizumab usage of management of CRS.

    Time frame: Within the first year on study

  15. Median Tocilizumab Usage

    Median tocilizumab usage is defined as median number of doses of tocilizumab administered per participant

    Time frame: Within the first year on study

  16. Grade 3-5 Adverse Events Rate

    Grade 3-5 AE rate is defined as the proportion of patients who experienced grade 3-5 adverse event based on the Common Toxicity Criteria for Adverse Events version 5.0 as reported on case report form.

    Time frame: Adverse events will be collected at each study visit plus 30 days post treatment end

  17. Treatment-related Adverse Events Rate

    Treatment-related adverse event rate is defined as the proportion of participants who experienced treatment-related adverse event based on the Common Toxicity Criteria for Adverse Events version 5.0.

    Time frame: Adverse events will be collected at each study visit plus 30 days post treatment end

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2028, 47 months after the start.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 47 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Jan 22, 2024
Primary completionEst.
Jan 15, 2028
CompletionEst.
Jan 15, 2033
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
8 inclusion criteria edited, 4 added; 9 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedMust have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven transformation to large B-cell lymphoma (LBCL), consistent with Richter's Transformation. The diagnostic sample must be reviewed by the treating institution.
  • AddedTumor sample may be obtained by core needle or excisional surgical biopsy.
  • EditedMust have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven transformation to diffuse large B-cell lymphoma (DLBCL), consistent with Richter's Transformation. The diagnostic sample must be reviewed by the treating institution. Tumor sample may be obtained by core needle or excisional surgical biopsy. A fresh biopsy is encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided. Biopsy can be obtained up to 3 months prior to first day of treatment.
  • AddedBiopsy can be obtained up to 3 months prior to first day of treatment.
  • AddedMeasurable disease, defined as ≥1 measurable nodal lesion (long axis >1.5 cm or short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on PET, CT, or magnetic resonance imaging (MRI). Disease should be FDG-avid based on PET.
  • EditedAbsolute neutrophil count must be > 1.0 x10\^9x109/L (growth factor allowed to achieve), unless patients have significant bone marrow involvement of their malignancy confirmed on biopsy.
  • EditedPlatelets must be > 30 x10\^9x109/L, independent of transfusion within 7 days of screening, unless patients have bone marrow involvement of their malignancy confirmed on biopsy
  • EditedCreatinine < 2.0 x ULN (upper limit of normal) or estimated CrCl > 50 ml/min according to Cockcroft/Gault formula
  • Editedo Subjects with Gilbert's Syndrome or resolving autoimmune hemolytic anemia may have a bilirubin up to 3.0 X ULN
  • EditedWillingness to remain abstinent (refrain from heterosexual intercourse) or to use highly effective contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least the following durations listed below:
  • EditedFemale patients: at least 18 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 5 months after the last dose of atezolizumab, or 9 months after the last dose of polatuzumab vedotin, or 3 months after the last dose of tocilizumab (if applicable), or 1 month after the last dose of pirtobrutinib, whichever whichever is longest.
  • EditedMale patients: at least 36 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 56 months after the last dose of polatuzumab vedotin, or 2 months after the last dose of tocilizumab (if applicable), whichever is longest.
Exclusion criteria
  • EditedNo prior anti-CD20 bispecific antibody is allowed. No prior, polatuzumab vedotin is allowed for patients in the polatuzumab vedotin-containing combination arm. No prior, or atezolizumab therapy is allowed for patients in the atezolizumab-containing combination arm. No prior pirtobrutinib is allowed for patients in the pirtobrutinib-containing arm.
  • EditedSubject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of treatment: investigational agents, targeted therapies, e.g. tyrosine kinase inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not limited to, CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, radio-immunoconjugates, antibody-drug conjugatesconjugates1, immune/cytokines and monoclonal antibodies. Patients who are currently receiving treatment with an agent targeting Bruton's tyrosine kinase may continue this agent until the day prior to starting treatment, to reduce the risk of tumor flare on treatment cessation (patients in the pirtobrutinib combination arm may not have received an antibody-drug conjugate within 28 days prior to the first dose of study treatment), immune/cytokines and monoclonal antibodies. Patients who are currently receiving treatment with a Bruton's tyrosine kinase inhibitor may continue this agent until the day prior to starting treatment, to reduce the risk of tumor flare on treatment cessation.
  • EditedFor patients receiving polatuzumab vedotin: Current > Grade 12 peripheral neuropathy.
  • EditedCurrent or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease (Note: patients with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years6 months and have no residual neurologic deficits, as judged by the investigator, are permitted).
  • EditedFor patients enrolling to the pirtobrutinib combination arm, patients with the following shouldwill be discussed with the Sponsor-Investigator prior to enrollmentexcluded: active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.
  • EditedPatients, who have had a major surgery or significant traumatic injury within 42 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
  • EditedFor patients in all other cohorts, only those without controlled disease (controlled disease defined as CD4 count greater than or equal to≥ 200 per microliter/uL, undetectable viral load, and stable anti-retroviral therapy) will be excluded.
  • EditedClinically significant liver disease, including cirrhosis and active viral or non-viral hepatitis. Patients who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative viral load (by PCR testing), be willing to undergo regular testing, and be able to be treated with a prophylactic agent (e.g. entecavir) if indicated (see Section 5.5). Patients with hepatitis C seropositivity are eligible only if they have a negative viral load (by PCR testing).
  • AddedPatients with a known active infection.
  • EditedPatients with a known active infection or any major episode of infection requiring hospitalization within 2 weeks prior to first study drug or treatment with IV antimicrobial-directed antimicrobials within 4 weeks1 week prior to first study drug. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation), antivirals, or antifungals may participate.
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact d•••@email.unc.edu→c•••@unchealth.unc.eduContact person changed (no phone or email listed)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Eligibility 8 inclusion criteria edited, 4 added; 9 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedMust have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven transformation to large B-cell lymphoma (LBCL), consistent with Richter's Transformation. The diagnostic sample must be reviewed by the treating institution.
    • AddedTumor sample may be obtained by core needle or excisional surgical biopsy.
    • EditedMust have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven transformation to diffuse large B-cell lymphoma (DLBCL), consistent with Richter's Transformation. The diagnostic sample must be reviewed by the treating institution. Tumor sample may be obtained by core needle or excisional surgical biopsy. A fresh biopsy is encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided. Biopsy can be obtained up to 3 months prior to first day of treatment.
    • AddedBiopsy can be obtained up to 3 months prior to first day of treatment.
    • AddedMeasurable disease, defined as ≥1 measurable nodal lesion (long axis >1.5 cm or short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on PET, CT, or magnetic resonance imaging (MRI). Disease should be FDG-avid based on PET.
    • EditedAbsolute neutrophil count must be > 1.0 x10\^9x109/L (growth factor allowed to achieve), unless patients have significant bone marrow involvement of their malignancy confirmed on biopsy.
    • EditedPlatelets must be > 30 x10\^9x109/L, independent of transfusion within 7 days of screening, unless patients have bone marrow involvement of their malignancy confirmed on biopsy
    • EditedCreatinine < 2.0 x ULN (upper limit of normal) or estimated CrCl > 50 ml/min according to Cockcroft/Gault formula
    • Editedo Subjects with Gilbert's Syndrome or resolving autoimmune hemolytic anemia may have a bilirubin up to 3.0 X ULN
    • EditedWillingness to remain abstinent (refrain from heterosexual intercourse) or to use highly effective contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least the following durations listed below:
    • EditedFemale patients: at least 18 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 5 months after the last dose of atezolizumab, or 9 months after the last dose of polatuzumab vedotin, or 3 months after the last dose of tocilizumab (if applicable), or 1 month after the last dose of pirtobrutinib, whichever whichever is longest.
    • EditedMale patients: at least 36 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 56 months after the last dose of polatuzumab vedotin, or 2 months after the last dose of tocilizumab (if applicable), whichever is longest.
    Exclusion criteria
    • EditedNo prior anti-CD20 bispecific antibody is allowed. No prior, polatuzumab vedotin is allowed for patients in the polatuzumab vedotin-containing combination arm. No prior, or atezolizumab therapy is allowed for patients in the atezolizumab-containing combination arm. No prior pirtobrutinib is allowed for patients in the pirtobrutinib-containing arm.
    • EditedSubject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of treatment: investigational agents, targeted therapies, e.g. tyrosine kinase inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not limited to, CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, radio-immunoconjugates, antibody-drug conjugatesconjugates1, immune/cytokines and monoclonal antibodies. Patients who are currently receiving treatment with an agent targeting Bruton's tyrosine kinase may continue this agent until the day prior to starting treatment, to reduce the risk of tumor flare on treatment cessation (patients in the pirtobrutinib combination arm may not have received an antibody-drug conjugate within 28 days prior to the first dose of study treatment), immune/cytokines and monoclonal antibodies. Patients who are currently receiving treatment with a Bruton's tyrosine kinase inhibitor may continue this agent until the day prior to starting treatment, to reduce the risk of tumor flare on treatment cessation.
    • EditedFor patients receiving polatuzumab vedotin: Current > Grade 12 peripheral neuropathy.
    • EditedCurrent or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease (Note: patients with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years6 months and have no residual neurologic deficits, as judged by the investigator, are permitted).
    • EditedFor patients enrolling to the pirtobrutinib combination arm, patients with the following shouldwill be discussed with the Sponsor-Investigator prior to enrollmentexcluded: active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.
    • EditedPatients, who have had a major surgery or significant traumatic injury within 42 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
    • EditedFor patients in all other cohorts, only those without controlled disease (controlled disease defined as CD4 count greater than or equal to≥ 200 per microliter/uL, undetectable viral load, and stable anti-retroviral therapy) will be excluded.
    • EditedClinically significant liver disease, including cirrhosis and active viral or non-viral hepatitis. Patients who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative viral load (by PCR testing), be willing to undergo regular testing, and be able to be treated with a prophylactic agent (e.g. entecavir) if indicated (see Section 5.5). Patients with hepatitis C seropositivity are eligible only if they have a negative viral load (by PCR testing).
    • AddedPatients with a known active infection.
    • EditedPatients with a known active infection or any major episode of infection requiring hospitalization within 2 weeks prior to first study drug or treatment with IV antimicrobial-directed antimicrobials within 4 weeks1 week prior to first study drug. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation), antivirals, or antifungals may participate.
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact d•••@email.unc.edu→c•••@unchealth.unc.eduContact person changed (no phone or email listed)
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06043674
Lead sponsor
Christine Ryan
Responsible party
Christine Ryan (Principal Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Sep 21, 2023
Start date
Jan 22, 2024
Primary completion
Jan 15, 2028 (estimated)
Completion
Jan 15, 2033 (estimated)
Last update
Oct 21, 2026

Study contacts

Celeste Carey, MS
Contact
celeste_carey@dfci.harvard.edu
857-215-1646
Christine Ryan, MD
Contact
christine_ryan@dfci.harvard.edu
Christine Ryan, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polatuzumab vedotin · Atezolizumab · Pirtobrutinib

Start the discussion